CANCER TREATMENT COMBINATIONS

1 . A method of treating a cancer or tumor in an individual, the method comprising administering to the individual afflicted with the cancer or tumor an effective amount of:

a) a histone deacetylase inhibitor (HDACi); b) a nucleoside analog; c) and a checkpoint inhibitor antagonist.

2 . The method of claim 1 , wherein the HDACi comprises vorinostat, romidepsin, mocetinostat, belinostat, pracinostat, givinostat, panobinostat, CUDC-101, zabinostat, chidamide, domatinostat, entinostat, and combinations thereof.

3 . The method of claim 1 wherein the HDACi comprises nanatinostat.

4 . The method of claim 3 , wherein the nanatinostat is administered at a dose of about 5 milligrams to about 160 milligrams per day.

5 . The method of claim 3 , wherein the nanatinostat is administered at a dose of about 5 milligrams to about 80 milligrams per day.

6 . The method of claim 3 , wherein the nanatinostat is administered at a dose of about 5 milligrams to about 40 milligrams per day.

7 . The method of claim 3 , wherein the nanatinostat is administered at a dose of about 5 milligrams to about 20 milligrams per day.

8 . The method of claim 3 , wherein the nanatinostat is administered at a dose of about 10 milligrams to about 20 milligrams per day.

9 . The method of claim 3 , wherein the nanatinostat is administered at a dose of about 10 milligrams to about 40 milligrams per day.

10 . The method of claim 3 , wherein the nanatinostat is administered at a dose of about 10 milligrams per day.

11 . The method of claim 3 , wherein the nanatinostat is administered at a dose of about 20 milligrams per day.

12 . The method of claim 3 , wherein the nanatinostat is administered at a dose of about 40 milligrams per day.

13 . The method of claim 12 , wherein the nanatinostat is administered orally.

14 . The method of claim 13 , wherein the nanatinostat is administered b.i.d.

15 . The method of claim 13 , wherein the nanatinostat is administered q.d.

16 . The method of claim 1 , wherein the nucleoside analog is a substrate of a viral thymidine kinase.

17 . The method of claim 1 , wherein the nucleoside analog comprises valganciclovir, ganciclovir, acyclovir, valaciclovir, famciclovir or a combination thereof.

18 . The method of claim 1 , wherein the nucleoside analog comprises valganciclovir.

19 . The method of claim 18 , wherein the valganciclovir is administered at dose of about 900 milligrams per day.

20 . The method of claim 18 , wherein the valganciclovir is administered at dose of about 450 milligrams per day.

21 . The method of claim 1 , wherein the checkpoint inhibitor antagonist is an antibody that binds to and inhibits the function of a checkpoint inhibitor.

22 . The method of claim 1 , wherein the checkpoint inhibitor comprises PD-1, PD-L1, PD-L2, or CTLA4.

23 . The method of claim 22 , wherein the checkpoint inhibitor comprises PD-1.

24 . The method of claim 23 , wherein the checkpoint inhibitor antagonist comprises nivolumab, pembrolizumab, cemiplimab, or a combination thereof.

25 . The method of claim 22 , wherein the checkpoint inhibitor comprises PD-L1.

26 . The method of claim 25 , wherein the checkpoint inhibitor antagonist comprises atezolizumab, avelumab, durvalumab, or a combination thereof.

27 . The method of claim 22 , wherein the checkpoint inhibitor comprises CTLA4.

28 . The method of claim 27 , wherein the checkpoint inhibitor antagonist comprises ipilimumab.

29 . The method of claim 1 , wherein the checkpoint inhibitor antagonist is administered intravenous.

30 . The method of claim 1 , wherein the checkpoint inhibitor antagonist is administered subcutaneous.

31 . The method of claim 1 , wherein the checkpoint inhibitor is administered at a dose of about 200 milligrams.

32 . The method of claim 1 , wherein the checkpoint inhibitor is administered at a dose of about 400 milligrams.

33 . The method of claim 1 , wherein the checkpoint inhibitor is administered at a dose of from about 1 milligram per kilogram to about 12 milligrams per kilogram.

34 . The method of claim 1 , wherein the checkpoint inhibitor is administered at a dose of about 2 milligrams per kilogram.

35 . The method of claim 1 , wherein the checkpoint inhibitor is administered at a dose of about 10 milligrams per kilogram.

36 . The method of claim 1 , wherein the checkpoint inhibitor is administered at a dose of about 300 milligrams.

37 . The method of claim 1 , wherein the checkpoint inhibitor is administered at a dose of about 240 milligrams.

38 . The method of claim 1 , wherein the checkpoint inhibitor is administered at a dose of about 350 milligrams.

39 . The method of claim 1 , wherein the checkpoint inhibitor is administered at a dose of about 480 milligrams.

40 . The method of claim 1 , wherein the checkpoint inhibitor is administered once every two weeks.

41 . The method of claim 1 , wherein the checkpoint inhibitor is administered once every three weeks.

42 . The method of claim 1 , wherein the checkpoint inhibitor is administered once every four weeks.

43 . The method of claim 1 , wherein the checkpoint inhibitor is administered once every six weeks.

44 . The method of claim 3 , wherein the nanatinostat is administered on a weekly schedule and the individual is administered nanatinostat for 2 days of the weekly schedule.

45 . The method of claim 3 , wherein the nanatinostat is administered on a weekly schedule and the individual is administered the nanatinostat for 3 days of the weekly schedule.

46 . The method of claim 3 , wherein the nanatinostat is administered on a weekly schedule and the individual is administered the nanatinostat for 4 days of the weekly schedule.

47 . The method of claim 44 , wherein the weekly schedule is repeated one or more times.

48 . The method of claim 1 , wherein the cancer or tumor is a lymphoproliferative disorder.

49 . The method of claim 48 , wherein the lymphoproliferative disorder is B cell lymphoma or leukemia.

50 . The method of claim 48 , wherein the lymphoproliferative disorder is T cell lymphoma or leukemia.

51 . The method of claim 48 , wherein the lymphoproliferative disorder is a Hodgkin's lymphoma, a non-Hodgkin's lymphoma, or Burkitt's lymphoma.

52 . The method of claim 1 , wherein the cancer or tumor is a solid tumor.

53 . The method of claim 1 , wherein the cancer or tumor is a Herpesviridae associated cancer.

54 . The method of claim 1 , wherein the cancer or tumor is associated with human cytomegalovirus (CMV), Epstein-Barr virus (EBV), or herpes simplex virus 1 or 2 (HSV-1 or -2).

55 . The method of claim 1 , wherein the cancer or tumor is associated with Epstein-Barr virus (EBV).

56 . The method of claim 1 , wherein the cancer or tumor is an Epstein-Barr virus positive cancer or tumor.

57 . The method of claim 1 , wherein the cancer or tumor comprises a latent Epstein-Barr virus infection.

58 . The method of claim 1 , wherein the cancer or tumor is breast cancer, non-small cell lung cancer, melanoma, head and neck, lymphoepithelioma-like carcinoma, bladder, gastric cancer, nasopharyngeal carcinoma, leiomyosarcoma, or colorectal cancer.

59 . The method of claim 1 , wherein the cancer or tumor is nasopharyngeal carcinoma, leiomyosarcoma, lymphoepithelioma-like carcinoma, or gastric cancer.

60 . The method of claim 59 , wherein the cancer or tumor is nasopharyngeal carcinoma.

61 . A method of treating an EBV-associated cancer or tumor in an individual, the method comprising administering to the individual afflicted with the cancer or tumor an effective amount of: a) nanatinostat; b) aciclovir, ganciclovir, valaciclovir, valganciclovir, or famciclovir; c) and a PD-1/PD-L1 axis inhibitor.

62 . The method of claim 61 , wherein the PD-1/PD-L1 axis inhibitor comprises nivolumab, pembrolizumab, cemiplimab, atezolizumab, avelumab, and durvalumab.

63 . The method of claim 61 , wherein the PD-1/PD-L1 axis inhibitor comprises nivolumab, pembrolizumab, or cemiplimab.

64 . The method of claim 61 , wherein the PD-1/PD-L1 axis inhibitor comprises pembrolizumab.

65 . The method of claim 61 , wherein the EBV-associated cancer is nasopharyngeal carcinoma, leiomyosarcoma, lymphoepithelioma-like carcinoma, or gastric cancer.

66 . The method of claim 61 , wherein the EBV-associated cancer is nasopharyngeal carcinoma.